BC
EBS icon

Bridgefront Capital’s Emergent Biosolutions EBS Stock Holding History

Bridgefront Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-25,880
Closed -$268K – 515
2023
Q1 		$268K Buy
+25,880
New +$313K 0.16% 245
2021
Q2 		– Sell
-7,765
Closed -$721K – 671
2021
Q1 		$721K Buy
+7,765
New +$795K 0.22% 123

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bridgefront Capital's EBS Position: Q2 2023 in Review

Bridgefront Capital sold out of Emergent Biosolutions (EBS) in Q2 2023, closing a stake of 25,880 shares — an estimated $268K sold.

Bridgefront Capital first reported a position in EBS in Q1 2021 and held it in 2 quarters. The position peaked at $721K in Q1 2021. 183 funds tracked by Wall St. Rank hold EBS as of Q2 2023.

  • Bridgefront Capital reported no remaining Emergent Biosolutions position as of Q2 2023 after selling out during the quarter.
  • Bridgefront Capital sold 25,880 Emergent Biosolutions shares in Q2 2023, an estimated $268K.
  • Bridgefront Capital first reported a position in Emergent Biosolutions in Q1 2021 and held it in 2 quarters.
  • Bridgefront Capital's Emergent Biosolutions position peaked at $721K in Q1 2021.
  • 183 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2023.

Based on Bridgefront Capital's 13F filing for Q2 2023, filed 14 Aug 2023.